Immunotherapies are changing the landscape of advanced solid tumor treatment. These therapies have different mechanisms of action and include oncolytic viruses, checkpoint inhibitors, such as CTLA-4 or PD1/PD-L1 monoclonal antibodies, and CSF-1R antibodies. Given the growing therapeutic impact of these agents in oncology, it is important to better understand their properties. Immunotherapies generate new toxicity profiles that are called immune-related adverse events and require specific management. This review focuses on the mechanisms of action of such side effects, as well as their description and their general management.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pharmthera.2017.07.005 | DOI Listing |
Publication Analysis
Top Keywords
toxicity profiles
8
mechanisms action
8
profiles immunotherapy
4
immunotherapy immunotherapies
4
immunotherapies changing
4
changing landscape
4
landscape advanced
4
advanced solid
4
solid tumor
4
tumor treatment
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!